Genitourinary tumours, non-prostate
Invited discussant abstracts 773PD, 774PD, 775PD and 776PD
Date
09 Oct 2016Session
Genitourinary tumours, non-prostatePresenters
Manuela SchmidingerAuthors
M. SchmidingerAuthor affiliations
- Vienna General Hospital (AKH) - Medizinische Universität Wien, 1090 - Vienna/AT
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
3309 - Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer (mUC) who have received prior treatment: Results from the phase II CheckMate 275 study
Presenter: Matthew Galsky
Session: Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
2626 - Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study
Presenter: Arjun Balar
Session: Genitourinary tumours, non-prostate
Resources:
Abstract
Immunotherapy will be “THE OPTION” in first and second line urothelial tumors
Presenter: Laurence Albiges
Session: Genitourinary tumours, non-prostate
Resources:
Slides
Webcast
Chemotherapy will always remain “THE BACKBONE” in urothelial tumor
Presenter: Viktor Grünwald
Session: Genitourinary tumours, non-prostate
Resources:
Slides
Webcast
2577 - Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): Preliminary safety and efficacy results
Presenter: Michael Atkins
Session: Genitourinary tumours, non-prostate
Resources:
Abstract
4232 - A phase I study of cabozantinib plus nivolumab (CaboNivo) in patients (pts) refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors
Presenter: Andrea Apolo
Session: Genitourinary tumours, non-prostate
Resources:
Abstract
2513 - Phase 1b dose-finding study of avelumab (anti-PD-L1) + axitinib in treatment-naïve patients with advanced renal cell carcinoma
Presenter: James Larkin
Session: Genitourinary tumours, non-prostate
Resources:
Abstract
1779 - A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients with selected solid tumors
Presenter: Matthew Taylor
Session: Genitourinary tumours, non-prostate
Resources:
Abstract
2534 - Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma progressed after platinum-based therapy or platinum ineligible
Presenter: Manish Patel
Session: Genitourinary tumours, non-prostate
Resources:
Abstract
1888 - Quality of life (QoL) and neurotoxicity in germ-cell cancer survivors (GCCS)
Presenter: Jakob Lauritsen
Session: Genitourinary tumours, non-prostate
Resources:
Abstract